Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors
Pictured: 3D illustration of the proteasome enzyme/iStock, Love Employee Biohaven on Wednesday unveiled Phase I data for its protein degrader BHV-1300, touting a rapid, substantial and selective reduction in levels of autoantibody IgG in healthy volunteers. However, investors were not impressed with BHV-1300’s performance as Biohaven’s shares dropped 12.6% in reaction to the readout, according